Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer (Nature (2017) 547 (109-113) DOI: 10.1038/nature22964);MTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

Nature

Volumn 547, Issue 7661, 2017, Pages 109-113

  Zabala Letona, Amaia ^a,b   Arruabarrena Aristorena, Amaia ^a   Martín Martín, Natalia ^a,b   Fernandez Ruiz, Sonia ^a,b   Sutherland, James D ^a   Clasquin, Michelle ^c   Tomas Cortazar, Julen ^a   Jimenez, Jose ^d   Torres, Ines ^d   Quang, Phong ^c   Ximenez Embun, Pilar ^e   Bago, Ruzica ^f   Ugalde Olano, Aitziber ^g   Loizaga Iriarte, Ana ^g   Lacasa Viscasillas, Isabel ^g   Unda, Miguel ^g   Torrano, Verónica ^a,b   Cabrera, Diana ^a   Van Liempd, Sebastiaan M ^a   Cendon, Ylenia ^e,h   Castro, Elena ^e   Murray, Stuart ^c   Revandkar, Ajinkya ^i,j   Alimonti, Andrea ^i,j   Zhang, Yinan ^k   Barnett, Amelia ^c   Lein, Gina ^c   Pirman, David ^c   Cortazar, Ana R ^a   Arreal, Leire ^a   Prudkin, Ludmila ^d   Astobiza, Ianire ^a   Valcarcel Jimenez, Lorea ^a   Zuñiga García, Patricia ^a   Fernandez Dominguez, Itziar ^a   Piva, Marco ^a   Caro Maldonado, Alfredo ^a   Sánchez Mosquera, Pilar ^a   Castillo Martín, Mireia ^l,m   Serra, Violeta ^d   Beraza, Naiara ^a,v   Gentilella, Antonio ^n,o   Thomas, George ⁿ   Azkargorta, Mikel ^a,b   Elortza, Felix ^a,b,p   Farràs, Rosa ^q   Olmos, David ^e,r   Efeyan, Alejo ^e   Anguita, Juan ^a,s   Muñoz, Javier ^b,e   Falcón Pérez, Juan M ^a,p,s   Barrio, Rosa ^a   Macarulla, Teresa ^b,d   Mato, Jose M ^a,p   Martinez Chantar, Maria L ^a,p   Cordon Cardo, Carlos ^l   Aransay, Ana M ^a,p   Marks, Kevin ^c   Baselga, José ^t   Tabernero, Josep ^b,d   Nuciforo, Paolo ^d   Manning, Brendan D ^k   Marjon, Katya ^c   Carracedo, Arkaitz ^a,b,s,u   more..

^a CIC BIOGUNE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c AGIOS PHARMACEUTICALS   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Structural Biology and Biocomputing Programme   (Spain)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g HOSPITAL DE BASURTO   (Spain)

^h UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

ⁱ INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^j UNIVERSITY OF LAUSANNE   (Switzerland)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m CHAMPALIMAUD FOUNDATION   (Portugal)

ⁿ BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^o UNIVERSITY OF BARCELONA   (Spain)

^p INSTITUTO DE SALUD CARLOS III   (Spain)

^q CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^r CNIO IBIMA Genito Urinary Cancer Unit   (Spain)

^s BASQUE FOUNDATION FOR SCIENCE   (Spain)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^u UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^v INSTITUTE OF FOOD RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSYLMETHIONINE DECARBOXYLASE; ADENOSYLMETHIONINE DECARBOXYLASE 1; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; POLYAMINE; UNCLASSIFIED DRUG; AMD1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; S ADENOSYLMETHIONINE; S-ADENOSYL-3-METHYLTHIOPROPYLAMINE; TARGET OF RAPAMYCIN KINASE;

CANCER; CELLS AND CELL COMPONENTS; ENZYME; GROWTH; INHIBITOR; METABOLISM; ORGANIC COMPOUND; PHYSIOLOGY; POLYMER; PROTEIN; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; MALE; MOUSE; NONHUMAN; POLYAMINE METABOLISM; PRIORITY JOURNAL; PROSTATE CANCER; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYME ACTIVATION; HUMAN; IMMUNOLOGY; METABOLISM; METABOLOMICS; PATHOLOGY; PROSTATIC NEOPLASMS; PROTEIN STABILITY;

ADENOSYLMETHIONINE DECARBOXYLASE; ANIMALS; CELL PROLIFERATION; ENZYME ACTIVATION; EVEROLIMUS; HUMANS; MALE; METABOLOMICS; MICE; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASES; POLYAMINES; PROSTATIC NEOPLASMS; PROTEIN STABILITY; PTEN PHOSPHOHYDROLASE; S-ADENOSYLMETHIONINE; TOR SERINE-THREONINE KINASES;

EID: 85022206445     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature25470     Document Type: Erratum

References (49)

1. Efeyan, A., Comb, W. C. & Sabatini, D. M. Nutrient-sensing mechanisms and pathways. Nature 517, 302-310 (2015).
2. Ben-Sahra, I. & Manning, B. D. mTORC1 signaling and the metabolic control of cell growth. Curr. Opin. Cell Biol. 12, 72-82 (2017).
3. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
4. Ugalde-Olano, A. et al. Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. Methods 77-78, 25-30 (2015).
5. Tabernero, J. et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26, 1603-1610 (2008).
6. Carracedo, A. & Pandolfi, P. P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27, 5527-5541 (2008).
7. Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619 (2006).
8. Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283-296 (2012).
9. Pegg, A. E. S-Adenosylmethionine decarboxylase. Essays Biochem. 46, 25-45 (2009).
10. Xiong, H. & Pegg, A. E. Mechanistic studies of the processing of human S-adenosylmethionine decarboxylase proenzyme. Isolation of an ester intermediate. J. Biol. Chem. 274, 35059-35066 (1999).
11. Kryukov, G. V. et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214-1218 (2016).
12. Marjon, K. et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Reports 15, 574-587 (2016).
13. Mavrakis, K. J. et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351, 1208-1213 (2016).
14. Shlomi, T., Fan, J., Tang, B., Kruger, W. D. & Rabinowitz, J. D. Quantitation of cellular metabolic fluxes of methionine. Anal. Chem. 86, 1583-1591 (2014).
15. Eskens, F. A. et al.; European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. Clin. Cancer Res. 6, 1736-1743 (2000).
16. Paridaens, R. et al. A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br. J. Cancer 83, 594-601 (2000).
17. Regenass, U. et al. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res. 54, 3210-3217 (1994).
18. Siu, L. L. et al. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies. Clin. Cancer Res. 8, 2157-2166 (2002).
19. Serra, H. et al. PTEN mediates Notch-dependent stalk cell arrest in angiogenesis. Nat. Commun. 6, 7935 (2015).
20. Greenberg, N. M. et al. Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA 92, 3439-3443 (1995).
21. Origanti, S. et al. Ornithine decarboxylase mRNA is stabilized in an mTORC1-dependent manner in Ras-transformed cells. Biochem. J. 442, 199-207 (2012).
22. Bale, S. & Ealick, S. E. Structural biology of S-adenosylmethionine decarboxylase. Amino Acids 38, 451-460 (2010).
23. Zhang, Y. et al. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 513, 440-443 (2014).
24. Ouyang, D. Y. et al. Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy 9, 20-32 (2013).
25. Hsu, P. P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-1322 (2011).
26. Zhao, J., Zhai, B., Gygi, S. P. & Goldberg, A. L. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc. Natl Acad. Sci. USA 112, 15790-15797 (2015).
27. Huang, Z. et al. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future Oncol. 11, 1687-1699 (2015).
28. O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
29. Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074 (2008).
30. Gerner, E. W. & Meyskens, F. L., Jr. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4, 781-792 (2004).
31. Song, M. S. et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144, 187-199 (2011).
32. Chen, Z. et al. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci. Signal. 2, ra44 (2009).
33. Motameni, A. R. et al. Delivery of the immunosuppressive antigen Salp15 to antigen-presenting cells by Salmonella enterica serovar Typhimurium aroA mutants. Infect. Immun. 72, 3638-3642 (2004).
34. Torrano, V. et al. The metabolic co-regulator PGC1 suppresses prostate cancer metastasis. Nat. Cell Biol. 18, 645-656 (2016).
35. Dowling, R. J. et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172-1176 (2010).
36. Wiederschain, D. et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8, 498-504 (2009).
37. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783-784 (2014).
38. Carracedo, A. et al. A metabolic prosurvival role for PML in breast cancer. J. Clin. Investigation 122, 3088-3100 (2012).
39. Salazar, M. et al. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. Cell Death Differ. 22, 131-144 (2015).
40. Alimonti, A. et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681-693 (2010).
41. Revandkar, A. et al. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. Nat. Commun. 7, 13719 (2016).
42. Fuhrer, T., Heer, D., Begemann, B. & Zamboni, N. High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. Anal. Chem. 83, 7074-7080 (2011).
43. Jha, A. K. et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42, 419-430 (2015).
44. Melamud, E., Vastag, L. & Rabinowitz, J. D. Metabolomic analysis and visualization engine for LC-MS data. Anal. Chem. 82, 9818-9826 (2010).
45. Fumagalli, S., Ivanenkov, V. V., Teng, T. & Thomas, G. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev. 26, 1028-1040 (2012).
46. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
47. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811-816 (2004).
48. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
49. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51 (2007).